Triple-Negative Breast Cancer Study Touted As Most Cited In AACR Journal

Triple-Negative Breast Cancer Study Touted As Most Cited In AACR Journal
During its annual meeting, the American Association for Cancer Research (AACR) announced that a scientific report describing a drug targeting the unprecedented genomic sequencing of 14 metastatic triple-negative breast cancers was the most cited study in the year of 2013 of any paper published that year by Molecular Cancer Therapeutics, AACR’s journal. This study revealed drugs that target very difficult-to-treat metastatic triple-negative breast cancer (TNBC) thanks to genomic sequencing. “Genome and transcriptome sequencing in prospective triple negative breast cancer uncovers therapeutic vulnerabilities” was conducted by the Translational Genomics Research Institute (TGen) and US Oncology Research with support from Life Technologies Corporation. TGen, US Oncology Research and Baylor University Medical Center researchers discovered relevant recurring mutations and other alterations in over 12 genes in patients treated at Baylor University Medical Center at Dallas. Furthermore, they managed to identify mutations that were never seen before in metastatic TNBC, crossing it with sequencing data to select specific therapeutic protocols according to the genetic profile of each patient. “The nature of this disease cried out for innovative research techniques such as whole genome sequencing coupled with new tools for data analysis,” explained David Craig, co-lead author, the TGen's Deputy Director of Bioinformatics. Researchers found that the most frequently mutated gene among tumors was TP53, a tumor suppressor gene, al
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.